ViGenCell Inc.
Financials
Valuation Metrics
ViGenCell Inc.'s Market Cap is ₩1054B. At end of 2025 it was ₩1999B. Ranked #1212 of 2,436 in KR market (top 50%), #646 of 1,649 on KOSDAQ (top 39%), #139 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 105.37B KRW | KR#1,212/2,436 Sec#139/234 |
| Revenue | 351.4M KRW | KR#2,397/2,436 Sec#224/234 |
| Net Income | -16.34B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 50.26B KRW | KR#2,190/2,436 Sec#198/234 |
| Net Assets | 43.72B KRW | KR#1,967/2,436 Sec#170/234 |
| Employees | 63 | KR#1,919/2,436 Sec#168/234 |
| Value | ||
| P/B | 2.41x | KR#2,021/2,436 Sec#153/234 |
| P/S | 299.86x | KR#2,404/2,436 Sec#220/234 |
| FCF Yield | -13.11% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -37.37% | KR#2,218/2,436 Sec#184/234 |
| ROA | -32.50% | KR#2,316/2,436 Sec#206/234 |
| Op. Margin | -4911.28% | KR#2,398/2,436 Sec#224/234 |
| Revenue Growth | -91.87% | KR#2,342/2,436 Sec#211/234 |
| Financial Health | ||
| Debt Ratio | 114.96% | KR#540/2,436 Sec#72/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -13.82B KRW | KR#1,808/2,436 Sec#164/234 |
| Cash | 5.11B KRW | KR#1,974/2,436 Sec#179/234 |
| Current Ratio | 18.99x | KR#30/2,436 Sec#11/234 |
| Performance | ||
| 1Y Return | 44.59% | KR#264/2,436 Sec#22/234 |
| 1M Return | -9.51% | KR#1,728/2,436 Sec#175/234 |
| From 52W High | -70.39% | KR#2,148/2,436 Sec#195/234 |
| 1Y MDD | -71.96% | KR#2,023/2,436 Sec#177/234 |
| Trading | ||
| Volume | 107,128 shares | KR#903/2,436 Sec#90/234 |
| Foreign Own. | 1.22% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -798 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,007 KRW | KR#2,025/2,436 Sec#168/234 |
Company Info
Established in 2013, the company is a bio venture specializing in pharmaceutical research and development and immune cell therapy development. Based on HLA research from The Catholic University of Korea College of Medicine, it develops immunotherapies using human blood-derived immune cells and is a cell therapy specialist with domestic clinical trial experience in antigen-specific killer T-cell research. Utilizing its ViTier platform technology, the company is developing treatments for NK/T-cell lymphoma and acute myeloid leukemia. Vaxcell-Bio was established in 2013 and is headquartered in Seoul-si, Geumcheon-gu.